Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427880 | 1.00 | LOXL2 (0.42) | LOXL2RPS6KA3PREPFAPNUDT1 | |
| Water SCHEMBL1278453 | 0.98 | LOXL2 (0.41) | LOXL2RPS6KA3PREPFAPNUDT1 | |
| SCHEMBL29954161 | 0.82 | LOXL2 (0.38) | LOXL2RPS6KA3PREPFAP | |
| SCHEMBL1129426 | 0.82 | LOXL2 (0.38) | LOXL2RPS6KA3PREPFAP | |
| SCHEMBL708913 | 0.74 | SIRT3 (0.41) | SIRT3TDP1 | |
| SCHEMBL22489854 | 0.74 | KDM4E (0.38) | RPS6KA3SIRT3TDP1 | |
| SCHEMBL29952734 | 0.74 | KDM4E (0.38) | RPS6KA3SIRT3TDP1 | |
| SCHEMBL2471793 | 0.74 | GPR119 (0.32) | LOXL2 | |
| SCHEMBL1896645 | 0.73 | ALDH1A1 (0.45) | SIRT3TDP1 | |
| SCHEMBL115776 | 0.73 | GAA (0.46) | PREPFAPSIRT3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403449-A1 | BIPHENYL DIARYL PYRIMIDINE DERIVATIVE WITH AROMATIC HETEROCYCLIC STRUCTURE | FUDAN UNIVERSITY (CN) | 2021-12-30 | — | — | US | claimed |
| EP-4735114-A1 | SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES | Masarykova Univerzita (CZ) | 2026-05-06 | — | — | EP | disclosed |
| EP-4737448-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND USE THEREOF | Artivila (ShenZhen) Innovation Center, Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025235872-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-12383548-B2 | Antibacterial quinolines | Tecnimede—Sociedade Técnico-Medicinal, SA (PT) | 2025-08-12 | — | — | US | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006114606-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1682126-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006044753-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005037273-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383548-B2 | Antibacterial quinolines | NQO2, RABGGTB, NQO1 | LOXL2 3778/4885RPS6KA3 437/4885PREP 1015/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | LOXL2 2158/4885RPS6KA3 373/4885PREP 3322/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | LOXL2 4092/4885RPS6KA3 3835/4885PREP 1872/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | LOXL2 2063/4885RPS6KA3 2434/4885PREP 688/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | LOXL2 2206/4885RPS6KA3 355/4885PREP 2348/4885 |
| US-20210403449-A1 | BIPHENYL DIARYL PYRIMIDINE DERIVATIVE WITH AROMATIC HETEROCYCLIC STRUCTURE | DPYD, TYMP, DHODH | LOXL2 4204/4885RPS6KA3 4813/4885PREP 1333/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | LOXL2 3872/4885RPS6KA3 2260/4885PREP 3679/4885 |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | LOXL2 2484/4885RPS6KA3 197/4885PREP 3835/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | LOXL2 1993/4885RPS6KA3 2866/4885PREP 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.